Pipeline
Development Assets
Status for all assets progressed into full development
PHASE 2
Camoteskimab is an anti-IL18 mAb being developed as a novel therapeutic for inflammatory indications such as atopic dermatitis
PHASE 2
APL-9796 is a first in class, disease modifying anti-ZIP12 mAb being developed for pulmonary hypertension
PHASE 2
APL-18881 is a bispecific FGF21/GLP-1 dual receptor agonist (bispecific fusion protein) in undisclosed indication
PHASE 1
APL-4098 is a highly selective and potent small molecule GCN2 inhibitor being developed as a novel therapeutic for liquid tumors
PHASE 1
APL-5125 is a highly selective and potent small molecule CK2α inhibitor being developed as a novel therapeutic for solid tumors
IND ENABLING
APL-10456 is a rhinovirus vaccine to prevent exacerbations of major chronic lung conditions
DISCOVERY PIPELINE
We have over fifteen active drug discovery and pre-clinical therapeutic programs, almost all of which are based on breakthroughs in biology and basic medical research made at our partner universities and institutions. Our R&D philosophy is explained below.
Expanded Access
Apollo evaluates expanded access requests on a case-by-case basis, consistent with the Expanded Access Policy.
Please contact Apollo with any questions or requests at medicalinfo@apollotx.com